Owkin Doses First Patient in Phase I Trial of AI-Optimized Cancer Therapy OKN4395
What You Should Know:
– Owkin, an AI-powered biotech company, today announced the dosing of the first patient in its Phase I clinical trial of OKN4395, a novel cancer therapy designed to restore immune function…
Continue Reading